Bristol-Myers Squibb Company (BMY) Loss Submission Form

The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Bristol-Myers Squibb Company (NYSE: BMY) who purchased shares between January 27, 2015 and October 9, 2016. The action, which was filed in the United States District Court for the Northern District of California, alleges that the Company violated federal securities laws.

In particular, the BMY lawsuit alleges that (1) that Bristol-Myers' CheckMate-026 trial was more likely to fail than Defendants were representing; (2) that Bristol- Myers' CheckMate-026 trial failed more severely than the Company indicated in its August 5, 2016 announcements and disclosures; and (3) that, as a result of the foregoing, Defendants' statements about Bristol-Myers' business, operations, and prospects, were materially false and/or misleading and/or lacked a reasonable basis. On August 5, 2016, Bristol-Myers revealed that its CheckMate-026 trial exploring the use of Opdivo (nivolumab) as monotherapy failed to meet its primary endpoint of progression-free survival. Following this news, Bristol-Myers stock fell 16% to close at $63.28 per share on August 5, 2016. Then on October 9, 2016, Bristol-Myers revealed the final primary analysis of CheckMate-026, and that the overall Opdivo survival was only 14.4 months compared to chemotherapy's 13.2 months. Following this news, Bristol-Myers stock dropped over 10%, to close at $49.81 per share on October 10, 2016.

Shareholders have until April 10, 2018 to petition the court for lead plaintiff status. Your ability to share in any recovery does not require that you serve as lead plaintiff. You may choose to be an absent class member.

Please fill out the form to learn more

Keep Me Informed

There is no cost or obligation. This submission does not create an attorney-client relationship. If we believe that you might be an appropriate lead plaintiff, we will contact you to discuss whether to establish an attorney-client relationship.

I am ready to join the action

This letter confirms that you have retained The Klein Law Firm to represent you as a named plaintiff in a shareholder action involving Bristol-Myers Squibb Company.

We agree to advance all expenses in the litigation, which means that you are not liable to pay any of the expenses of the lawsuit, whether attorneys' fees or costs. Regardless of the result, we will never ask you to directly pay for any attorneys' fees or costs. Should we obtain a favorable result, we may ask the court to award us compensation to be paid by the defendants or as a portion of any class benefit, but, again, we will never ask you to directly pay any of the costs of this litigation.

As the client you are entitled to direct the litigation in any way you deem proper, and may at any time order us to dismiss the case or opt-out. Should you choose to do so, we will never ask you to reimburse us directly for any legal fees or expenses. During the course of this litigation, we may employ and/or work with other law firms to prosecute your case.

We look forward to representing you and other Bristol-Myers Squibb Company shareholders.

Sincerely,

The Klein Law Firm

Joseph Klein

AGREED: Sign Name Clear